Literature DB >> 31953646

Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?

Stephanie Shiau1, Stephen M Arpadi2, Michael T Yin3.   

Abstract

PURPOSE OF REVIEW: In the era of modern bone-friendly antiretroviral therapy (ART) regimens for people living with HIV (PLWH), this review discusses the research gaps and management concerns that remain for individuals who have already been exposed to ART with negative effects on bone metabolism, especially children and adolescents who have not acquired peak bone mass, and older adults who have additional risk factors for fracture. RECENT
FINDINGS: Data now support the use of avoidance of TDF and use of bone-friendly regimens that include integrase strand transfer inhibitors in PLWH with increased risk of fracture for either ART initiation or switch. Despite significant advances in our understanding of ART choice for PLWH with regard to bone health, additional diagnostic tests to determine fracture risk and management strategies beyond ART choice are necessary, especially in vulnerable PLWH populations, such as children and adolescents and older adults.

Entities:  

Keywords:  Bone mineral density; Fracture; Osteoporosis

Mesh:

Substances:

Year:  2020        PMID: 31953646      PMCID: PMC8815400          DOI: 10.1007/s11904-019-00474-1

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  41 in total

Review 1.  Incident fractures in HIV-infected individuals: a systematic review and meta-analysis.

Authors:  Stephanie Shiau; Emily C Broun; Stephen M Arpadi; Michael T Yin
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

2.  Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents: Risk Factors and the Role of T-cell Activation and Senescence.

Authors:  Beatriz Jiménez; Talía Sainz; Laura Díaz; María José Mellado; María Luisa Navarro; Pablo Rojo; María Isabel González-Tomé; Luis Prieto; Jorge Martínez; María Isabel de José; José Tomás Ramos; María Ángeles Muñoz-Fernandez
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

3.  Bone Quality Measured Using Calcaneal Quantitative Ultrasonography Is Reduced Among Children with HIV in Johannesburg, South Africa.

Authors:  Stephen M Arpadi; Cara B Thurman; Faeezah Patel; Jonathan J Kaufman; Renate Strehlau; Megan Burke; Stephanie Shiau; Ashraf Coovadia; Michael T Yin
Journal:  J Pediatr       Date:  2019-08-29       Impact factor: 4.406

4.  Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.

Authors:  Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

5.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

6.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Authors:  Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; Nancy Liu; Craig M Wilson; Rohan Hazra; Sybil G Hosek; Peter L Anderson; Sharon M Seifert; Bill G Kapogiannis; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2016-11-15       Impact factor: 9.079

7.  Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

Authors:  Mark J Bolland; Andrew Grey; Anne M Horne; Simon E Briggs; Mark G Thomas; Rod B Ellis-Pegler; Greg D Gamble; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

8.  HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine.

Authors: 
Journal:  J Adolesc Health       Date:  2018-10       Impact factor: 5.012

9.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.

Authors:  Kathleen Mulligan; D Robert Harris; Patricia Emmanuel; Roger A Fielding; Carol Worrell; Bill G Kapogiannis; Dina Monte; John Sleasman; Craig M Wilson; Grace M Aldrovandi
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

10.  Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.

Authors:  Grace A McComsey; Sergio Lupo; David Parks; Mónica Coronado Poggio; Joseph De Wet; Lesley P Kahl; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Martin Gartland; Michael Cupo; Michael Aboud
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

View more
  3 in total

1.  Hormone therapy and fractures in postmenopausal women.

Authors:  Michael T Yin; Donald R Hoover; Qiuhu Shi; Phyllis C Tien; Mardge H Cohen; Seble Kassaye; Deborah Gustafson; Adaora Adimora; M Neale Weitzmann; Hector Bolivar; Amy Warriner; Sara H Bares; Anjali Sharma
Journal:  AIDS       Date:  2022-06-22       Impact factor: 4.632

Review 2.  Bone Quality in Relation to HIV and Antiretroviral Drugs.

Authors:  Arnold Z Olali; Kelsey A Carpenter; Maria Myers; Anjali Sharma; Michael T Yin; Lena Al-Harthi; Ryan D Ross
Journal:  Curr HIV/AIDS Rep       Date:  2022-06-20       Impact factor: 5.495

Review 3.  Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis.

Authors:  María Victoria Delpino; Jorge Quarleri
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.